Parkinson’s disease and psychoses;Parkinson-Krankheit und Psychosen

Neuropsychiatrie

Volumn 29, Issue 1, 2015, Pages

  Bizzarri, Jacopo Vittoriano ^a   Giupponi, Giancarlo ^a   Maniscalco, Ignazio ^a   Schroffenegger, Patrizia ^a   Conca, Andreas ^a   Kapfhammer, Hans Peter ^b  

^a S Maurizio Hospital   (Italy)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Clinical picture; Organic psychosis; Parkinson s syndrome; Pathophysiology; Therapy

Indexed keywords

ANTIPARKINSON AGENT;

BRAIN; COMORBIDITY; DELIRIUM, DEMENTIA, AMNESTIC, COGNITIVE DISORDERS; DOSE RESPONSE; DRUG EFFECTS; HUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PSYCHOSES, SUBSTANCE-INDUCED; RISK FACTOR;

ANTIPARKINSON AGENTS; BRAIN; COMORBIDITY; DELIRIUM, DEMENTIA, AMNESTIC, COGNITIVE DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; PARKINSON DISEASE; PSYCHOSES, SUBSTANCE-INDUCED; RISK FACTORS;

EID: 84922386947     PISSN: 09486259     EISSN: 21941327     Source Type: Journal    
DOI: 10.1007/s40211-014-0132-8     Document Type: Review

References (159)

1. Global Parkinson’s Disease Survey Steering Committee. Factors impacting on quality of life in Parkinson’s disease: results from an international survey. Mov Disord. 2002;17:60–7.
2. Goetz CG, Stebbins GT. Risk factors for nursing home placement in advanced Parkinson’s disease. Neurology. 1993;43:2227–9.
3. Goetz CG, Stebbins GT. Mortality and hallucinations in nursing home patients with advanced Parkinson’s disease. Neurology. 1995;45:669–71.
4. Carter JH, Stewart BJ, Archbold PG, et al. Living with a person who has Parkinson’s disease: the spouse’s perspective by stage of disease. Mov Disord. 1998;13:20–8.
5. Aarsland D, Larsen JP, Karlsen K, Lim NG, Tandberg E. Mental symptoms in Parkinson’s disease are important contributors to caregiver distress. Int J Geriatr Psychiatry. 1999;14:866–74.
6. Aarsland D, Larsen JP, Tandberg E, Laake K. Predictors of nursing home placement in Parkinson’s disease: a population-based, prospective study. J Am Geriatr Soc. 2000;48:938–42.
7. Factor SA, Feustel PJ, Friedman JH, Comella CL, Goetz CG, Kurlan R, Parsa M, Pfeiffer R. Parkinson Study Group. Longitudinal outcome of Parkinson’s disease patients with psychosis. Neurology. 2003;60:1756–61.
8. Aarsland D, Bronnick K, Ehrt U, et al. Neuropsychiatric symptoms in patients with Parkinson’s disease and dementia: frequency, profile and associated care giver stress. J Neurol Neurosurg Psychiatry. 2007;78(1):36–42.
9. McKinlay A, Grace RC, Dalrymple-Alford JC, et al. A profile of neuropsychiatric problems and their relationship to quality of life for Parkinson’s disease patients without dementia. Parkinsonism Relat Disord. 2008;14:37–42.
10. Aarsland D, Larsen JP, Cummins JL, Laake K. Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study. Arch Neurol. 1999;56(5):595–601.
11. Lauterbach EC. The neuropsychiatry of Parkinson’s disease and related disorders. Psychiatr Clin North Am. 2004;27:801–25.
12. Marsh L, Williams JR, Rocco M, Grill S, Munro C, Dawson TM. Psychiatric comorbidities in patients with Parkinson disease and psychosis. Neurology. 2004;63(2):293–300.
13. Weintraub D, Morales KH, Duda JE, Moberg PJ, Stern MB. Frequency and correlates of co-morbid psychosis and depression in Parkinson’s disease. Parkinsonism Relat Disord. 2006;12:427–31.
14. Fénelon G, Alves G. Epidemiology of psychosis in Parkinson’s disease. J Neurol Sci. 2010;289(1–2):12–7.
15. Holt RJ, Sklar AR, Darkow T, Goldberg GA, Johnson JC, Harley CR. Prevalence of Parkinson’s disease-induced psychosis in a large U.S. managed care population. J Neuropsychiatry Clin Neurosci. 2010;22(1):105–10.
16. Mack J, Rabins P, Anderson K, Goldstein S, Grill S, Hirsch ES, Lehmann S, Little JT, Margolis RL, Palanci J, Pontone G, Weiss H, Williams JR, Marsh L. Prevalence of psychotic symptoms in a community-based Parkinson disease sample. Am J Geriatr Psychiatry. 2012;20(2):123–32.
17. Ravina B, Marder K, Fernandez HH, et al. Diagnostic criteria for psychosis in Parkinson’s disease: report of an NINDS/NIMH work group. Mov Disord. 2007;22(8):1061–8.
18. Marsh L. Psychosis in Parkinson’s disease. Curr Treat Options Neurol. 2004;6:181–9.
19. Papapetropoulos S, McCorquodale DS, Gonzalez J, Jean-Gilles L, Mash DC. Cortical and amygdalar Lewy body burden in Parkinson’s disease patients with visual hallucinations. Parkinsonism Relat Disord. 2006;12(4):253–6.
20. Sanchez-Ramos JR, Ortoll R, Paulson GW. Visual hallucinations associated with Parkinson’s disease. Arch Neurol. 1996;53(12):1265–8.
21. Fenelon G, Mahieux F, Huon R, Ziegler M. Hallucinations in Parkinson’s disease: prevalence, phenomenology and risk factors. Brain. 2000;123:733–45.
22. Barnes J, David AS. Visual hallucinations in Parkinson’s disease: a review and phenomenological survey. J Neurol Neurosurg Psychiatry. 2001;70(6):727–33.
23. Holroyd S, Currie L, Wooten GF. Prospective study of hallucinations and delusions in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2001;70(6):734–8.
24. Papapetropoulos S, Mash DC. Psychotic symptoms in Parkinson’s disease. From description to etiology. J Neurol. 2005;252(7):753–64. (REV).
25. Mosimann UP, Rowan EN, Partington CE, et al. Characteristics of visual hallucinations in Parkinson’s disease dementia and dementia with Lewy bodies. Am J Geriatr Psychiatry. 2006;14(2):153–60.
26. Inzelberg R, Kipervasser S, Korczyn AD. Auditory hallucinations in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1998;64(4):533–5.
27. Factor SA, Molho ES. Threatening auditory hallucinations and Cotard syndrome in Parkinson disease. Clin Neuropharmacol. 2004;27:205–7.
28. Fénelon G, Thobois S, Bonnet AM, Broussolle E, Tison F. Tactile hallucinations in Parkinson’s disease. J Neurol. 2002;249(12):1699–703.
29. Tousi B, Frankel M. Olfactory and visual hallucinations in Parkinson’s disease. Parkinsonism Relat Dis. 2004;10(4):253–4.
30. Goetz CG, Wuu J, Curgian L, Leurgans S. Age-related influences on the clinical characteristics of new-onset hallucinations in Parkinson’s disease patients. Mov Disord. 2006;21(2):267–70.
31. Williams DR, Warren JD, Lees AJ. Using the presence of visual hallucinations to differentiate Parkinson’s disease from atypical Parkinsonism. J Neurol Neurosurg Psychiatry. 2008 Jun;79(6):652–5.
32. de Maindreville AD Fenelon G Mahieux F. Hallucinations in Parkinson’s disease: a follow-up study. Mov Disord. 2005;20:212–7.
33. Fernandez HH, Trieschmann ME, Okun MS. Rebound psychosis: effect of discontinuation of antipsychotics in Parkinson’s disease. Mov Disord. 2005;20:104–5.
34. Pollak P, et al. Clozapine in drug induced psychosis in Parkinson’s disease: a randomized, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry. 2004;75:689–95.
35. Rabey JM. Hallucinations and psychosis in Parkinson’s disease. Parkinsonism Relat Disord. 2009; Suppl. 4:105–10.
36. Diederich NJ, Pieri V, Goetz CG. Coping strategies for visual hallucinations in Parkinson’s disease. Mov Disord. 2003;18:831–8.
37. Kiziltan G, Ôzekmekçi S, Ertan S, Ertan T, Erginöz E. Relationship between age and subtypes of psychotic symptoms in Parkinson’s disease. J Neurol. 2007;254(4):448–52.
38. Wolters EC. Intrinsic and extrinsic psychosis in Parkinson’s disease. J Neurol. 2001;248(Suppl 3): 22–7.
39. Wolters EC, Berendse HW. Management of psychosis in Parkinson’s disease. Curr Opin Neurol. 2001;14:499–504.
40. Goetz CG, Fan W, Leurgans S, Bernard B, Stebbins GT. The malignant course of „benign hallucinations“ in Parkinson’s disease. Arch Neurol. 2006;63:713–6.
41. Goetz CG, Leurgans S, Pappert EJ, Raman R, Stemer AB. Prospective longitudinal assessment of hallucinations in Parkinson’s disease. Neurology. 2001;57:2078–82.
42. Fernandez HH, Aarsland D, Fénelon G, et al. Scales to Assess psychosis in Parkinson’s disease: critique and recommendations. Mov Disord. 2008;23(4):484–500.
43. Aarsland D, et al. Range of neuropsychiatric disturbances in patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1999;67:492–6.
44. Holroyd S, Wooten GF. Preliminary fMRI evidence of visual system dysfunction in Parkinson’s disease patients with visual hallucinations. J Neuropsychiatry Clin Neurosci. 2006;18(3):402–4.
45. Schrag A, Ben-Shlomo Y, Quinn N. How common are complications of Parkinson’s disease. J Neurol. 2002;249(4):419–23.
46. Weintraub D, Chen P, Ignacio RV, Mamikonyan E, Kales HC. Patterns and trends in antipsychotic prescribing for Parkinson’s disease psychosis. Arch Neurol. 2011;68(7):899–904.
47. Graham JM, Grünewald RA, Sagar HJ. Hallucinosis in idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1997;63(4):434–40.
48. Pacchetti C, Manni R, Zangaglia R, et al. Relationship between hallucinations, delusions and REM behavior disorder in Parkinson’s disease. Mov Disord. 2005;20(11):1439–48.
49. Goodwin FK. Psychiatric side effects of levodopa in man. JAMA. 1971;218:1915–20.
50. Friedman A, Sienkiewicz J. Psychotic complications of long-term levodopa treatment of Parkinson’s disease. Acta Neurol Scand. 1991;84:111–3.
51. Factor SA, Molho ES, Podskalny GD, Brown D. Parkinson’s disease: drug-induced psychiatric states. Adv Neurol. 1995;65:115–38.
52. Rascol O, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. N Engl J Med. 2000;342:1484–91.
53. Parkinson Study Group. Pramipexole vs. levodopa as initial treatment for Parkinson’s disease: a randomized controlled trial. JAMA. 2000;284:1931–8.
54. Papapetropoulos S. Drug-induced psychosis in Parkinson’s disease: phenomenology and correlations among psychosis rating instruments. Clin Neuropharmacol. 2006;29:59.
55. Fox SH, Visanji NP, Johnston TH, Gomez-Ramirez J, Voon V, Brotchie JM. Dopamine receptor agonists and levodopa and inducing psychosis-like behavior in the MPTP primate model of Parkinson’s disease. Arch Neurol. 2006;63:1343–4.
56. Rondot P, de Recondo J, Coignet A, Ziegler M. Mental disorders in Parkinson’s disease after treatment with L-DOPA. Adv Neurol. 1984;40:259–69.
57. Fenelon G, Goetz CG, Karenberg A. Hallucinations in Parkinson’s disease in the prelevodopa era. Neurology. 2006;66:93–8.
58. Postma JU, Van Tilburg W. Visual hallucinations and delirium during treatment with amantadine (Symmetrel). J Am Geriatr Soc. 1975;23(5):212–5.
59. Klein C, Kompf D, Pulkowski U, Moser A, Vieregge P. A study of visual hallucinations in patients with Parkinson’s disease. J Neurol. 2007;244(6):371–7.
60. Moskovitz C, Moses H, Klawans HL. Levodopa-induced psychosis: a kindling phenomenon. Am J Psychiatry. 1978;135:669–75.
61. Wolters EC. Dopaminomimetic psychosis in Parkinson’s disease patients: diagnosis and treatment. Neurology. 1999;52:10–3.
62. Birkmayer W, Riederer P. Responsibility of extrastriatal areas for the appearance of psychotic symptoms (clinical and biochemical human post-mortem findings). J Neural Transm. 1975;37(2):175–82.
63. Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson’s disease. N Engl J Med. 1999;340:757–63.
64. Ballanger B, Strafella AP, van Eimeren T, et al. Serotonin 2A receptors and visual hallucinations in Parkinson’s disease. Arch Neurol. 2010;67:416–21.
65. Perry EK, et al. Evidence of a monoaminergic-cholinergic imbalance related to visual hallucinations in Lewy body dementia. J Neurochem. 1990;55(4):1454–6.
66. Whitehouse PJ. Clinical and neurochemical consequences of neuronal loss in the nucleus basalis of Meynert in Parkinson’s disease and Alzheimer’s disease. Adv Neurol. 1987;45:393–7.
67. Perry EK, Perry RH. Acetylcholine and hallucinations: disease-related compared to drug-induced alterations in human consciousness. Brain Cogn. 1995;28(3):240–58.
68. Francis PT, Perry EK. Cholinergic and other neurotransmitter mechanisms in Parkinson’s disease, Parkinson’s disease dementia, and dementia with Lewy bodies. Mov Disord. 2007;22(Suppl 17):351–7.
69. Kuhl DE, Minoshima S, Fessler JA, et al. In vivo mapping of cholinergic terminals in normal aging, Alzheimer’s disease, and Parkinson’s disease. Ann Neurol. 1996;40(3):399–410.
70. Perry EK, Walker M, Grace J, Perry R. Acetylcholine in mind: a neurotransmitter correlate of consciousness? Trends Neurosci. 1999;22:273–80.
71. Harding AJ, Broe GA, Halliday GM. Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain. 2002;125(Pt 2):391–403.
72. Williams DR, Lees AJ. Visual hallucinations in the diagnosis of idiopathic Parkinson’s disease: a retrospective autopsy study. Lancet Neurol. 2005;4(10):605–10.
73. Matsui H, Nishinaka K, Oda M, et al. Hypoperfusion of the visual pathway in parkinsonian patients with visual hallucinations. Mov Disord. 2006;21(12):2140–4.
74. Diederich NJ, Goetz CG, Raman R, Pappert EJ, Leurgans S, Piery V. Poor visual discrimination and visual hallucinations in Parkinson’s disease. Clin Neuropharmacol. 1998;21(5):289–95.
75. Diederich NJ, Raman R, Leurgans S, Goetz CG. Progressive worsening of spatial and chromatic processing deficits in Parkinson’s disease. Arch Neurol. 2002;59(8):1249–52.
76. Bodis-Wollner I. Neuropsychological and perceptual defects in Parkinson’s disease. Parkinsonism Relat Disord. 2003;9(Suppl 2):83–9.
77. Mosimann UP, et al. Visual perception in Parkinson disease dementia and dementia with Lewy bodies. Neurology 2004;63:2091–6.
78. Stebbins GT, Goetz CG, Carrillo MC, et al. Altered cortical visual processing in PD with hallucinations: an fMRI study. Neurology. 2004;63(8):1409–16.
79. Paleacu D, Schechtman E, Inzelberg R. Association between family history of dementia and hallucinations in Parkinson disease. Neurology. 2005;64(10):1712–5.
80. Makoff AJ, Graham JM, Arranz MJ, et al. Association study of dopamine receptor gene polymorphisms with drug-induced hallucinations in patients with idiopathic Parkinson’s disease. Pharmacogenetics. 2000;10(1):43–8.
81. Goetz CG, Burke PF, Leurgans S, et al. Genetic variation analysis in Parkinson’s disease patients with and without hallucinations: case-control study. Arch Neurol. 2001;58(2):209–13.
82. Wang J, Zhao C, Chen B, Liu ZL. Polymorphisms of dopamine receptor and transporter genes and hallucinations in Parkinson’s disease. Neurosci Lett. 2004;355(3):193–6.
83. Kiferle L, Ceravolo R, Petrozzi L, et al. Visual hallucinations in Parkinson’s disease are not influenced by polymorphisms of serotonin 5-HT2A receptor and transporter genes. Neurosci Lett. 2007;422(3):228–31.
84. De la Fuente-Fernandez R Nunez MA Lopez E. The apolipoprotein E epsilon 4 allele increases the risk of drug-induced hallucinations in Parkinson’s disease. Clin Neuropharmacol. 1999;22(4):226–30.
85. Feldman B, Chapman J, Korczyn AD. Apolipoprotein epsilon4 advances appearance of psyhosis in patients with Parkinson’s disease. Acta Neurol Scand 2006;113(1):14–7.
86. Camicioli R, Rajput A, Rajput M, Reece C, Payami H, Hao C, Rajput A. Apolipoprotein E epsilon4 and catechol-O-methyltransferase alleles in autopsy-proven Parkinson’s disease: relationship to dementia and hallucinations. Mov Disord. 2005;20(8):989–94.
87. Factor SA, Steenland NK, Higgins DS, Molho ES, Kay DM, Montimurro J, Rosen AR, Zabetian CP, Payami H. Disease-related and genetic correlates of psychotic symptoms in Parkinson’s disease. Mov Disord. 2011;26(12):2190–5.
88. Aarsland D, Ballard C, Larsen JP, McKeith I. A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson’s disease with and without dementia. Int J Geriatr Psychiatry. 2001;16(5):528–36.
89. Giladi N, Treves A, Paleacu D, et al. Risk factors for dementia, depression, and psychosis in long-standing Parkinson’s disease. J Neural Transm. 2000;107(1):59–71.
90. Biglan KM, Holloway RG, McDermott MP, Richard IH, Parkinson Study Group CALM-PD Investigators. Risk factors for somnolence, edema, and hallucinations in early Parkinson disease. Neurology. 2007;69(2):187–95.
91. Sawada H, Oeda T, Yamamoto K, Umemura A, Tomita S, Hayashi R, Kohsaka M, Kawamura T. Trigger medications and patient-related risk factors for Parkinson’s disease psychosis requiring anti-psychotic drugs: a retrospective cohort study. BMC Neurol. 2013;13(1):145.
92. Pappert EJ, Goetz CG, Niederman FG, et al. Hallucinations, sleep fragmentation, and altered dream phenomena in Parkinson’s disease. Mov Disord. 1999;14(1):117–21.
93. Goetz CG, Wuu J, Curgian LM, Leurgans S. Hallucinations and sleep disorders in PD. Six-year prospective longitudinal study. Neurology. 2005;64(1):81–6.
94. Comella CL, Tanner CM, Ristanovic RK. Polysomnographic sleep measures in Parkinson’s disease patients with treatment-induced hallucinations. Ann Neurol. 1993;34(5):710–4.
95. Arnulf I, Bonnet A-M, Damier P, et al. Hallucinations, REM sleep, and Parkinson’s disease: a medical hypothesis. Neurology. 2000;55(2):281–8.
96. Fernandez HH, Friedman JF. The role of atypical antipsychotics in the treatment of movement disorders. CNS Drugs. 1999;11(6):467–83. 92.
97. Friedman JH, Fernandez HH. The non-motor problems of Parkinson’s disease. Neurology. 2000;6:18–27.
98. Henderson MJ, Mellers JDC. Psychosis in Parkinson’s disease: „between a rock and a hard place“. Int Rev Psychiatry. 2000;12:319–34.
99. Frieling H, Hillemacher T, Ziegenbein M, Neundorfer B, Bleich S. Treating dopamimetic psychosis in Parkinson’s disease: structured review and meta-analysis. Eur Neuropsychopharmacol. 2007;17(3):165–71.
100. Seppi K, Weintraub D, Coelho M, Perez-Lloret S, Fox SH, Katzenschlager R, Hametner EM, Poewe W, Rascol O, Goetz CG, Sampaio C. The movement disorder society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson’s disease. Mov Disord. 2011;26(Suppl 3):42–80.
101. Honigfeld G, Arellano F, Sethi J, et al. Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry. J Clin Psychiatry. 1998;59(Suppl 3):3–7.
102. Mohr E, Mendis T, Hildebrand K, et al. Risperidone in the treatment of dopamine-induced psychosis in Parkinson’s disease: an open pilot trial. Mov Disord. 2000;15:1230–7.
103. Parsa MA, Lebedeva, Z, Riley D, Poggi E, Lebedeva T. Low-dose risperidone in the treatment of levodopa-induced psychosis and dyskinesia in patients with Parkinson’s disease. Poster, Annual Meeting of International College of Geriatric Psychoneuropharmachology, San Juan, Puerto Rico, December 12–14, 2003.
104. Workman RH Jr., Orengo CA, Bakey AA, Molinari VA, Kunik ME. The use of risperidone for psychosis and agitation in demented patients with Parkinson’s disease. J Neuropsychiatry Clin Neurosci. 1997;9(4):594–7.
105. Rich SS, Friedman JH, Ott BR. Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson’s disease and other akinetic-rigid syndromes. J Clin Psychiatry. 1995;56:556–9.
106. Ellis T, Cudkowicz ME, Sexton PM, et al. Clozapine and risperidone treatment of psychosis in Parkinson’s disease. J Neuropsychiatry Clin Neurosci. 2000;12:364–69.
107. Meco G, Alessandri A, Giustini P, et al. Risperidone in levodopa-induced psychosis in advanced Parkinson’s disease: an open-label, long-term study. Mov Disord. 1997;12:610–2.
108. Rustembegovic A, Sofic E, Wichart I. Serum prolactin, leptin, lipids and lipoproteins levels during antipsychotics treatment in Parkinson's disease and related psychosis. Med Arh. 2006;60(4):211–2.
109. Molho ES, Factor SA. Worsening of motor features of Parkinsonism with olanzapine. Mov Disord. 1999;14:1014–6.
110. Breier A, Sutton VK, Feldman PD, et al. Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson’s disease. Biol Psychiatry. 2002;52:438–45.
111. Ondo WG, Levy JK, Vuong KD, et al. Olanzapine treatment for dopaminergic-induced hallucinations. Mov Disord. 2002;17:1031–5.
112. Goetz CG, Blasucci LM, Leurgans S, et al. Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. Neurology. 2000;55:789–94.
113. Reddy S, Factor SA, Molho ES, et al. The effect of quetiapine on psychosis and motor function in parkinsonian patients with and without dementia. Mov Disord. 2002;17:676–81.
114. Fernandez HH, Trieschmann ME, Burke MA, et al. Long-term outcome of quetiapine use for psychosis among Parkinsonian patients. Mov Disord. 2003;18:510–4.
115. Ondo WG, Tintner R, Voung KD, et al. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson’s disease. Mov Disord. 2005;20(8):958–63.
116. Rabey JM, Prokhorov T, Miniovitz A, Dobronevsky E, Klein C. Effect of quetiapine in psychotic Parkinson’s disease patients: a double-blind labeled study of 3 months’ duration. Mov Disord. 2007;22(3):313–8.
117. Kurlan R, Cummings J, Raman R, Thal L, Alzheimer’s Disease Cooperative Study Group. Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. Neurology. 2007;68(17):1356–63.
118. Morgante L, Epifanio A, Spina E, et al. Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis. Clin Neuropharmacol. 2004;27:153–6.
119. Merims D, Balas M, Peretz C, Shabtai H, Giladi N. Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson’s disease psychosis. Clin Neuropharmacol. 2006;29(6):331–7.
120. Klein C, Prokhorov T, Miniovich A, Dobronevsky E, Rabey JM. Long-term follow-up (24 months) of quetiapine treatment in drug-induced Parkinson disease psychosis. Clin Neuropharmacol. 2006;29(4):215–9.
121. Bloomfield K, MacDonald L, Finucane G, Snow B, Roxburgh R. Use of antipsychotic medications in patients with Parkinson’s disease at Auckland City Hospital. Intern Med J. 2012;42(7):e151–6.
122. Gómez-Esteban JC, Zarranz JJ, Velasco F, Lezcano E, Lachen MC, Rouco I, Barcena J, Boyero S, Ciordia R, Allue I. Use of ziprasidone in parkinsonian patients with psychosis. Clin Neuropharmacol. 2005;28(3):111–4.
123. Schindehütte J, Trenkwalder C. Treatment of drug-induced psychosis in Parkinson's disease with ziprasidone can induce severe dose-dependent off-periods and pathological laughing. Clin Neurol Neurosurg. 2007;109(2):188–91.
124. Pintor L, Valldeoriola F, Baillés E, Martí MJ, Muñiz A, Tolosa E. Ziprasidone versus clozapine in the treatment of psychotic symptoms in Parkinson disease: a randomized open clinical trial. Clin Neuropharmacol. 2012;35(2):61–6.
125. Fernandez HH, Trieschmann ME, Friedman JH. Aripiprazole for drug-induced psychosis in Parkinson disease: preliminary experience. Clin Neuropharmacol. 2004;27:4–5.
126. Schonfeldt-Lecuona C, Connemann BJ. Aripiprazole and Parkinson’s disease psychosis. Am J Psychiatry. 2004;161:373–4.
127. Friedman JH, Berman RM, Goetz CG, et al. Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson’s disease. Mov Disord. 2006;21:2078–81.
128. Ott B, Lannon M. Exacerbation of parkinsonism by tacrine. Clin Neuropharmacol. 1992;15:322–5.
129. Hutchinson M, Fazzini E. Cholinesterase inhibition in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1996;61:324–5.
130. Bergman J, Lerner V. Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson’s disease. Clin Neuropharmacol. 2002;25:107–10.
131. Sobow T. Parkinson’s disease-related visual hallucinations unresponsive to atypical antipsychotics treated with cholinesterase inhibitors: a case series. Neurol Neurochir Pol. 2007;41(3):276–9.
132. Fabbrini G, Barbanti P, Aurilia C, et al. Donepezil in the treatment of hallucinations and delusions in Parkinson’s disease. Neurol Sci. 2002;23:41–3.
133. Kurita A, Ochiai Y, Kono Y, et al. The beneficial effect of donepezil on visual hallucinations in three patients with Parkinson’s disease. J Geriatr Psychiatry Neurol. 2003;16:184–8.
134. Aarsland D, Hutchinson M, Larsen JP. Cognitive, psychiatric and motor response to galantamine in Parkinson’s disease with dementia. Int J Geriatr Psychiatry. 2003;18:937–41.
135. Bullock R, Cameron A. Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson’s disease: a case series. Curr Med Res Opin. 2002;18:258–64.
136. Meltzer HY, Mills R, Revell S, Williams H, Johnson A, Bahr D, Friedman JH. Primavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson’s disease psychosis. Neuropsychopharmacology. 2010;35(4):881–92.
137. Hurwitz TA, Calne DB, Waterman K. Treatment of dopamimetic psychosis in Parkinson’s disease with electroconvulsive therapy. Can J Neurol Sci. 1988;15(1):32–4.
138. Factor SA, Molho ES, Brown DL. Combined clozapine and electroconvulsive therapy for the treatment of drug-induced psychosis in Parkinson’s disease. J Neuropsychiatry Clin Neurosci. 1995;7(3):304–7.
139. Ozer F, Meral H, Aydin B, et al. Electroconvulsive therapy in drug-induced psychiatric states and neuroleptic malignant syndrome. J ECT. 2005;21(2):125–7.
140. Muralidharan K, Thimmaiah R, Chakraborty V, Jain S. Bifrontal ECT for drug-induced psychosis in Parkinson’s disease. Indian J Psychiatry. 2011;53(2):156–8.
141. Ueda S, Koyama K, Okubo Y. Marked improvement of psychotic symptoms after electroconvulsive therapy in Parkinson disease. J ECT. 2010;26(2):111–5.
142. Usui C, Hatta K, Doi N, Kubo S, Kamigaichi R, Nakanishi A, Nakamura H, Hattori N, Arai H. Improvements in both psychosis and motor signs in Parkinson’s disease, and changes in regional cerebral blood flow after electroconvulsive therapy. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(7):1704–8.
143. Tagai K, Nagata T, Shinagawa S, Tsuno N, Ozone M, Nakayama K. Mirtazapine improves visual hallucinations in Parkinson's disease: a case report. Psychogeriatrics. 2013;13(2):103–7.
144. Normann C, Hesslinger B, Frauenknecht S, et al. Psychosis during chronic levodopa therapy triggered by the new antidepressive drug mirtazapine. Pharmacopsychiatry. 1997;30:263–5.
145. Ikeguchi K, Kuroda A. Mianserin treatment of patients with psychosis induced by antiparkinsonian drugs. Eur Arch Psychiatry Clin Neurosci. 1995;244(6):320–4.
146. Voon V, Lang AE. Antidepressants in the treatment of psychosis with comorbid depression in Parkinson’s disease. Clin Neuropharmacol. 2004;27:90–2.
147. Meco G, Bernardi S. Antidepressant use in treatment of psychosis with comorbid depression in Parkinson’s disease. Prof Neuropsychopharmacol Biol Psychiatry. 2007;31:311–3.
148. Lauterbach EC. Dopaminergic hallucinosis with fluoxetine in Parkinson’s disease. Am J Psychiatry. 1993;150:1750.
149. Cummings, J., Isaacson, S., Mills. R., Williams, H., Chi-Burris, K., Corbett, A., Dhall, R., Ballard, C. Pimavanserin for patients with Parkinson’s disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet. 2014;383(9916):533–40.
150. Poewe W. Nonmotor symptoms in Parkinson’s disease. In: Jankovic J, Tolosa E, Herausgebers. Parkinson’s disease & movement disorders. Philadelphia, Lippincott Williams & Wilkins; 2007.
151. Aarsland D, Marsh L, Schrag A. Neuropsychiatric symptoms in Parkinson’s disease. Mov Disord. 2009;24(15):2175–86.
152. Mollenhauer B, Förstl H, Deuschl G, Storch A, Oertel W, Trenkwalder C. Lewy body and Parkinsonian dementia: common, but often misdiagnosed conditions. Dtsch Arztebl Int 2010;107(39):684–91.
153. Poewe W. When a Parkinson’s disease patient starts to hallucinate. Pract Neurol. 2008;8(4):238–41.
154. Cummings JL. Behavioral complications of drug treatment of Parkinson’s disease. J Am Geriatr Soc. 1991;39:708–16.
155. Leopold NA. Risperidone treatment of drug-related psychosis in patients with parkinsonism. Mov Disord. 2000;15(2):301–4.
156. Wolters EC, Jansen EN, Tuynman-Qua HG, Bergmans PL. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson’s disease. Neurology. 1996;47(4):1085–7.
157. Ravina B, Putt M, Siderowf A, et al. Donepezil for dementia in Parkinson’s disease: a randomised, double blind, placebo controlled, crossover study. J Neurol Neurosurg Psychiatry. 2005;76(7):934–9.
158. Reading PJ, Luce AK, McKeith IG. Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial. Mov Disord. 2001;16(6):1171–4.
159. Burn D, Emre M, McKeith I, et al. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson’s disease. Mov Disord. 2006;21(11):1899–907.